MCID: APL001
MIFTS: 73

Aplastic Anemia malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Blood diseases, Bone diseases

Aliases & Classifications for Aplastic Anemia

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 26GTR, 29ICD10, 30ICD10 via Orphanet, 31ICD9CM, 34LifeMap Discovery®, 36MedGen, 37MedlinePlus, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 63The Human Phenotype Ontology, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Aplastic Anemia:

Name: Aplastic Anemia 51 34 11 47 69 12 37 13 67
Anemia Aplastic 47 26 49
Idiopathic Aplastic Anemia 47 53
Secondary Aplastic Anemia 47 67
Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2 26
Pulmonary Fibrosis, Idiopathic 51
 
Idiopathic Bone Marrow Failure 53
Aplastic Anemia, Idiopathic 67
Aplastic Anemia Idiopathic 47
Anemia, Aplastic 38
Aa 69

Characteristics:

Orphanet epidemiological data:

53
idiopathic aplastic anemia:
Age of onset: Adult; Age of death: adult

HPO:

63
aplastic anemia:
Inheritance: autosomal dominant inheritance
Onset and clinical course: adult onset, incomplete penetrance

Classifications:



External Ids:

Disease Ontology11 DOID:12449
ICD9CM31 284.9
MeSH38 D000741
NCIt44 C2870
Orphanet53 ORPHA88
UMLS via Orphanet68 C0348890
ICD10 via Orphanet30 D61.0
MESH via Orphanet39 C538494
MedGen36 C2684859

Summaries for Aplastic Anemia

About this section
MedlinePlus:37 Aplastic anemia is a rare but serious blood disorder. if you have it, your bone marrow doesn't make enough new blood cells. there are different types, including fanconi anemia. causes include toxic substances, such as pesticides, arsenic, and benzene radiation therapy and chemotherapy for cancer certain medicines infections such as hepatitis, epstein-barr virus, or hiv autoimmune disorders certain inherited conditions pregnancy in many people, the cause is unknown. symptoms include fatigue, weakness, dizziness, and shortness of breath. it can cause heart problems such as an irregular heartbeat, an enlarged heart, and heart failure. you may also have frequent infections and bleeding. your doctor will diagnose aplastic anemia based on your medical and family histories, a physical exam, and test results. once your doctor knows the cause and severity of the condition, he or she can create a treatment plan for you. treatments include blood transfusions, blood and marrow stem cell transplants, and medicines. nih: national heart, lung, and blood institute

MalaCards based summary: Aplastic Anemia, also known as anemia aplastic, is related to myelodysplastic syndrome and pulmonary fibrosis, idiopathic, and has symptoms including cirrhosis, aplastic anemia and bone marrow hypocellularity. An important gene associated with Aplastic Anemia is TERC (Telomerase RNA Component), and among its related pathways are Jak/STAT Signaling Pathway and Calcineurin-regulated NFAT-dependent transcription in lymphocytes. Affiliated tissues include bone, bone marrow and heart, and related mouse phenotypes are endocrine/exocrine gland and integument.

Disease Ontology:11 An anemia that is characterized by a deficiency of red blood cells, white blood cells and platelets produced by bone marrow.

NIH Rare Diseases:47 Aplastic anemia is a blood disorder caused by failure of the bone marrow to make enough new blood cells. Bone marrow is a sponge-like tissue inside the bones that makes stem cells that develop into red blood cells, white blood cells, and platelets. Symptoms may include: fatigue,weakness, dizziness, shortness of breath, frequent infections, and bleeding. Aplastic anemia can lead to other health concerns such as an irregular heartbeat, an enlarged heart, and heart failure. It can be caused by injury to blood stem cells due to exposure to certain drugs, chemotherapy, congenital disorders, drug therapy to suppress the immune system, pregnancy, radiation therapy, or toxins such as benzene or arsenic. When the cause is unknown, it is referred to as idiopathic aplastic anemia. In about half of all cases, no cause can be found. The condition can be acute or chronic. Last updated: 11/30/2016

OMIM:51 Aplastic anemia is a serious disorder of the bone marrow that affects between 2 and 5 persons per million per year.... (609135) more...

UniProtKB/Swiss-Prot:69 Aplastic anemia: A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. It is characterized by peripheral pancytopenia and marrow hypoplasia.

Wikipedia:70 Aplastic anemia is a rare disease in which the bone marrow and the hematopoietic stem cells that reside... more...

Description from OMIM:51 614743

Related Diseases for Aplastic Anemia

About this section

Diseases in the Aplastic Anemia family:

Aplastic Anemia, Ifng-Related Aplastic Anemia, Prf1-Related

Diseases related to Aplastic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 243)
idRelated DiseaseScoreTop Affiliating Genes
1myelodysplastic syndrome31.1CD55, CD59, CSF2, EPO, IL3, KITLG
2pulmonary fibrosis, idiopathic12.4
3helsmoortel-van der aa syndrome12.1
4amyloidosis aa12.0
5pulmonary fibrosis, idiopathic susceptibility12.0
6retinopathy aplastic anemia neurological abnormalities11.9
7aplastic anemia susceptibility, sbds-related11.9
8aplastic anemia, ifng-related11.9
9aplastic anemia, prf1-related11.9
10congenital hypoplastic anemia11.7
11bone marrow failure syndrome 111.6
12dyskeratosis congenita, autosomal dominant 611.5
13idiopathic interstitial pneumonia11.2
14eosinophilic fasciitis11.2
15revesz syndrome11.2
16alopecia areata11.1
17renal nutcracker syndrome11.0
18pulmonary fibrosis and/or bone marrow failure, telomere-related, 111.0
19dyskeratosis congenita, autosomal dominant 211.0
20dyskeratosis congenita, autosomal dominant 311.0
21dyskeratosis congenita, autosomal recessive 511.0
22baraitser rodeck garner syndrome11.0DKC1, TERC
23hermansky-pudlak syndrome 910.9NHP2, NOP10, TERT
24cerebellum agenesis hydrocephaly10.9DKC1, TERC, TERT
25convulsions benign familial neonatal dominant form10.9TERC, TERT, TINF2
26superior mesenteric artery syndrome10.9
27hyperlipidemia type 310.9
28tracheophageal fistula hypospadias10.9DKC1, TERC
29stampe sorensen syndrome10.9IFNG, IL3, TERT
30genuine diffuse phlebectasia10.9SBDS, TERC, TERT
31childhood malignant mesenchymoma10.9EPO, IFNG, IL3
32levic stefanovic nikolic syndrome10.9DKC1, TERT, TINF2
33recessive dystrophic epidermolysis bullosa-generalized other10.9NHP2, NOP10, TERT
34ror2-related robinow syndrome10.9TERC, TERT
35cyp2c19-related poor drug metabolism10.9CSF2, IL3, KITLG
36aarskog-scott syndrome10.9
377q11.23 duplication syndrome10.9
38severe nonproliferative diabetic retinopathy10.9CSF2, IL3
39myotonic dystrophy 110.9EPO, KITLG
40mental retardation, x-linked, snyder-robinson type10.9CD55, CD59, PIGA
41microcystic adenoma10.9CSF2, IL3, KITLG
42transient neonatal neutropenia10.9CSF2, EPO, IL3, KITLG
43methemoglobinemia10.9EPO, IL3
44immunodeficiency 2110.9
45dyskeratosis congenita, autosomal recessive 210.9
46dyskeratosis congenita, autosomal recessive 110.9
47dyskeratosis congenita, autosomal recessive 610.9
48pulmonary fibrosis and/or bone marrow failure, telomere-related, 410.9
49dyskeratosis congenita, autosomal recessive 310.9
50pulmonary fibrosis and/or bone marrow failure, telomere-related, 310.9

Comorbidity relations with Aplastic Anemia via Phenotypic Disease Network (PDN):


Acquired ThrombocytopeniaActive Peptic Ulcer Disease
Acute CystitisAcute Kidney Failure
Chronic Kidney FailureDecubitus Ulcer
Deficiency AnemiaFamilial Atrial Fibrillation
Heart DiseaseIschemic Heart Disease
Left Ventricular Outflow Tract ObstructionNeutropenia
OsteoporosisSideroblastic Anemia
HypothyroidismIron Deficiency Anemia
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Aplastic Anemia:



Diseases related to aplastic anemia

Symptoms for Aplastic Anemia

About this section

Symptoms by clinical synopsis from OMIM:

614743

Clinical features from OMIM:

614743,609135

Human phenotypes related to Aplastic Anemia:

 63 (show all 6)
id Description HPO Frequency HPO Source Accession
1 cirrhosis63 rare (5%) HP:0001394
2 aplastic anemia63 HP:0001915
3 bone marrow hypocellularity63 HP:0005528
4 leukemia63 HP:0001909
5 pulmonary fibrosis63 HP:0002206
6 premature graying of hair63 HP:0002216

UMLS symptoms related to Aplastic Anemia:


chest pain

Drugs & Therapeutics for Aplastic Anemia

About this section

Drugs for Aplastic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 233)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Cyclosporineapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 191579217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
2
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
3
Prednisoneapproved, vet_approvedPhase 4, Phase 2, Phase 1135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
4
IronapprovedPhase 4, Phase 3, Phase 211237439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
5
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
6
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 11202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
7
BenzocaineapprovedPhase 4, Phase 3, Phase 2, Phase 118921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
8
Deferasiroxapproved, investigationalPhase 4, Phase 3, Phase 289201530-41-85493381
Synonyms:
Deferasiroxum
Deferasiroxum [inn-latin]
 
Exjade
ICL 670
ICL 670a
deferasirox
9
MechlorethamineapprovedPhase 4, Phase 237751-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
 
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
10
Etanerceptapproved, investigationalPhase 4397185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
11
Posaconazoleapproved, investigational, vet_approvedPhase 453171228-49-2147912
Synonyms:
1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
171228-49-2
177571-33-4
4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
AC-1350
AC1L3W34
AC1LAHLQ
AKOS005145917
CHEBI:434337
CHEMBL1397
CHEMBL371938
CHEMBL371939
CID10532764
CID11520437
CID11542142
CID147912
CID468595
D02555
 
DB01263
HSDB 7421
LS-186118
LS-186988
LS-187630
MolPort-006-666-426
Noxafil
Noxafil (TN)
Noxafil, Posaconazole
Posaconazole
Posaconazole (USAN/INN)
Posaconazole SP
Posaconazole [USAN:INN:BAN]
Posaconazole in combination with MGCD290
S1257_Selleck
SCH-56592
SCH56592
Sch 56592
Spriafil
UNII-6TK1G07BHZ
X2N
posaconazole
12
SuccinylcholineapprovedPhase 4161306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
13
Radium Ra 223 dichlorideapproved, investigationalPhase 454444811-40-9
Synonyms:
Radium-223 chloride
 
Radium-223 dichloride
Xofigo
14
Darbepoetin alfaapproved, investigationalPhase 4, Phase 217311096-26-7, 209810-58-2
Synonyms:
 
Darbepoetin
Darbepoetin alfa,recombinant
15tannic acidapproved, NutraceuticalPhase 4, Phase 3, Phase 2, Phase 11892
16Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
17Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18109
18Antiparasitic AgentsPhase 4, Phase 2, Phase 12127
19Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112767
20Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112778
21HormonesPhase 4, Phase 3, Phase 2, Phase 113979
22Liver ExtractsPhase 4, Phase 2, Phase 13868
23Antiprotozoal AgentsPhase 4, Phase 11986
24HematinicsPhase 4, Phase 3, Phase 21630
25Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110627
26Calcineurin InhibitorsPhase 4, Phase 3, Phase 2, Phase 11597
27Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14474
28Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
29Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13615
30Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15674
31Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112770
32Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14694
33ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16045
34Epoetin alfaPhase 4, Phase 3, Phase 2645113427-24-0
35Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110355
36AntibodiesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16045
37Steroid Synthesis InhibitorsPhase 4, Phase 21718
38Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 23822
39Iron Chelating AgentsPhase 4, Phase 3, Phase 2222
40Chelating AgentsPhase 4, Phase 3, Phase 2, Phase 11365
41Anti-Inflammatory Agents, Non-SteroidalPhase 44295
42Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 1, Phase 26260
43MicronutrientsPhase 4, Phase 3, Phase 2, Phase 15802
44AnalgesicsPhase 4, Phase 3, Phase 1, Phase 211287
45Trace ElementsPhase 4, Phase 3, Phase 2, Phase 15802
46Neuromuscular Depolarizing AgentsPhase 4135
47Neuromuscular AgentsPhase 41129
48Neuromuscular Blocking AgentsPhase 4414
49Nitrogen Mustard CompoundsPhase 432
50
EverolimusapprovedPhase 2, Phase 3, Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus

Interventional clinical trials:

(show top 50)    (show all 345)
idNameStatusNCT IDPhase
1Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic AnemiaUnknown statusNCT01995331Phase 4
2Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic AnemiaUnknown statusNCT01997372Phase 4
3Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived)Unknown statusNCT02218437Phase 4
4Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic AnemiaCompletedNCT01546415Phase 4
5Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney FailureCompletedNCT00391287Phase 4
6Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in JapanCompletedNCT00503503Phase 4
7A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant ErythropoietinsCompletedNCT00211029Phase 4
8Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadCompletedNCT00673608Phase 4
9Fanconi Syndrome Due to ARVs in HIV-Infected PersonsCompletedNCT00499187Phase 4
10A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin TreatmentCompletedNCT00211042Phase 4
11A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin AlfaCompletedNCT00211068Phase 4
12Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another ErythropoietinCompletedNCT00210951Phase 4
13Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia PatientsRecruitingNCT01818726Phase 4
14The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic AnemiaRecruitingNCT02745717Phase 4
15Radium-223 Dichloride Long-term Follow-up ProgramRecruitingNCT02312960Phase 4
16A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference ErythropoActive, not recruitingNCT00773513Phase 4
17Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin AlfaEnrolling by invitationNCT02648126Phase 4
18ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic AnemiaNot yet recruitingNCT02838992Phase 4
19King's Invasive Aspergillosis Study IINot yet recruitingNCT02875743Phase 4
20A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin AntibodiesWithdrawnNCT00210977Phase 4
21Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic AnemiaUnknown statusNCT01145976Phase 3
22Safety and Efficacy of Eltrombopag at Escalated DosesUnknown statusNCT01880047Phase 3
23Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant DiseasesUnknown statusNCT01019876Phase 2, Phase 3
24Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal AnemiaUnknown statusNCT00238043Phase 3
25Comparing Therapies for the Treatment of Severe Aplastic AnemiaCompletedNCT00001626Phase 3
26Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic AnemiaCompletedNCT00004474Phase 3
27Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic DisordersCompletedNCT00000597Phase 3
28Eculizumab to Treat Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00098280Phase 3
29High Dose Cyclophosphamide for Treatment of SclerodermaCompletedNCT00501995Phase 3
30Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory AnemiaCompletedNCT00046930Phase 3
31Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002798Phase 3
32Stem Cell Transplant for Bone Marrow Failure SyndromesCompletedNCT00176878Phase 2, Phase 3
33Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3
34Iron Sucrose in Stage 3/4 Kidney DiseaseCompletedNCT00202345Phase 3
35Efficacy and Safety Study of GerEPOCompletedNCT00229099Phase 3
36Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)RecruitingNCT02773225Phase 2, Phase 3
37Study of Romiplostim(AMG531) in Subjects With Aplastic AnemiaRecruitingNCT02773290Phase 2, Phase 3
38Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAARecruitingNCT01844635Phase 3
39hATG+CsA vs hATG+CsA+Eltrombopag for SAARecruitingNCT02099747Phase 3
40Transfusion Strategy in Hematological Intensive Care UnitRecruitingNCT02461264Phase 3
41TBI Dose De-escalation for Fanconi AnemiaRecruitingNCT00352976Phase 2, Phase 3
42SCT for Dyskeratosis Congenita or SAAActive, not recruitingNCT00455312Phase 2, Phase 3
43Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerActive, not recruitingNCT00003816Phase 2, Phase 3
44Stem Cell Transplant for HemoglobinopathyActive, not recruitingNCT00176852Phase 2, Phase 3
45Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)TerminatedNCT01163942Phase 3
46Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology PatientsTerminatedNCT01343680Phase 3
47A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)TerminatedNCT02158936Phase 3
48Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) TreatmentTerminatedNCT01288131Phase 3
49A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast CancerTerminatedNCT00246597Phase 3
50Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)Unknown statusNCT00881933Phase 1, Phase 2

Search NIH Clinical Center for Aplastic Anemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Aplastic Anemia cell therapies at LifeMap Discovery.

Genetic Tests for Aplastic Anemia

About this section

Genetic tests related to Aplastic Anemia:

id Genetic test Affiliating Genes
1 Aplastic Anemia26
2 Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 226

Anatomical Context for Aplastic Anemia

About this section

MalaCards organs/tissues related to Aplastic Anemia:

35
Bone, Bone marrow, Heart, Myeloid, T cells, Kidney, Lung

Animal Models for Aplastic Anemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Aplastic Anemia:

40 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537910.8CD59, CSF2, IFNG, KITLG, NBN, PRF1
2MP:001077110.8CSF2, DKC1, EPO, IFNG, KITLG, PIGA
3MP:000538010.8CSF2, DKC1, EPO, IFNG, KITLG, MPL
4MP:000200610.7CSF2, DKC1, IFNG, KITLG, NBN, PIGA
5MP:000537810.6CSF2, DKC1, IFNG, KITLG, MPL, NBN
6MP:000537610.5CD59, CSF2, DKC1, EPO, IFNG, KITLG
7MP:000538410.5CD59, CSF2, DKC1, EPO, IFNG, KITLG
8MP:000538710.4CSF2, DKC1, EPO, IFNG, KITLG, MPL
9MP:001076810.3CD59, CSF2, DKC1, EPO, IFNG, KITLG
10MP:000539710.2CD55, CD59, CSF2, DKC1, EPO, IFNG
11MP:00053899.9CD59, CSF2, DKC1, IFNG, KITLG, NBN

Publications for Aplastic Anemia

About this section

Articles related to Aplastic Anemia:

(show top 50)    (show all 1013)
idTitleAuthorsYear
1
Hematopoietic stem cell transplantation for acquired aplastic anemia. (27607445)
2016
2
Gastric wall perforation secondary to presumed aspergillosis in a pediatric patient with aplastic anemia: A case report. (25881536)
2015
3
Frequency of Paroxysmal Nocturnal Hemoglobinuria Clones by Multiparametric Flow Cytometry in Pediatric Aplastic Anemia Patients of Indian Ethnic Origin. (26230286)
2015
4
Abnormal quantity and function of regulatory T cells in peripheral blood of patients with severe aplastic anemia. (25906694)
2015
5
Increased Bone Marrow (BM) Plasma Level of Soluble CD30 and Correlations with BM Plasma Level of Interferon (IFN)-I^, CD4/CD8 T-Cell Ratio and Disease Severity in Aplastic Anemia. (25383872)
2014
6
Abnormalities of quantities and functions of linker for activations of T cells in severe aplastic anemia. (24673455)
2014
7
Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia. (23724451)
2013
8
Respiratory and systemic infections in children with severe aplastic anemia on immunosuppressive therapy. (23836007)
2013
9
Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan. (23103680)
2013
10
Less could be better: the case for reducing the dose of cyclophosphamide for children undergoing allogeneic stem cell transplant for severe aplastic anemia. (23581860)
2013
11
Varicella-like cutaneous toxoplasmosis in a patient with aplastic anemia. (23390283)
2013
12
Successful autologous cord blood transplantation in a child with acquired severe aplastic anemia. (23464883)
2013
13
Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. (23585526)
2013
14
Aplastic anemia in association with a lymphoproliferative neoplasm: coincidence or causality? (21962338)
2012
15
Eltrombopag in refractory aplastic anemia. (22992084)
2012
16
Asymptomatic cerebral bleeds in patients with aplastic anemia. (22441845)
2012
17
Study on clinical characteristics and follow-up visit of acquired aplastic anemia associated with parvovirus B19 infection. (21830025)
2012
18
A promising new treatment for refractory aplastic anemia. (22762322)
2012
19
Comparison between matched related and alternative donors of allogeneic hematopoietic stem cells transplanted into adult patients with acquired aplastic anemia: multivariate and propensity score-matched analysis. (21220035)
2011
20
Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. (21963603)
2011
21
Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. (21034842)
2011
22
Transient aplastic anemia in Down's syndrome - a rare association. (21354344)
2011
23
Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. (21635205)
2011
24
Influence of immunosuppressive therapy on expression of TNF-I+/IFN-I^ in cytoplasm of peripheral blood lymphocytes of patients with aplastic anemia]. (21729551)
2011
25
A hospital-based case control study of aplastic anemia in Shanghai, China. (20026322)
2010
26
Telomerase gene mutation screening in Chinese patients with aplastic anemia. (19942288)
2010
27
TINF2 mutations in children with severe aplastic anemia. (19090550)
2009
28
Anti-moesin antibodies in the serum of patients with aplastic anemia stimulate peripheral blood mononuclear cells to secrete TNF-alpha and IFN-gamma. (19109204)
2009
29
Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. (19896085)
2009
30
Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. (19144661)
2009
31
Feasibility and eligibility of retreatment with rabbit anti-T lymphocyte globulin for aplastic anemia previously treated with horse anti-thymocyte globulin. (19728019)
2009
32
Alterations in hematopoietic microenvironment in patients with aplastic anemia. (20443870)
2009
33
Apoptosis induction and phosphorylated protein kinase C epsilon expression in 32D cells by sera from patients with aplastic anemia]. (18844064)
2008
34
Impaired expression of genes regulating homeostasis of stem hemopoietic cells in stromal cells of patients with aplastic anemia]. (18326231)
2008
35
A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodysplasia and aplastic anemia with raised ferritin levels. (18484675)
2008
36
Clinical implications of combined measurement bone marrow T cells intracellular IFNgamma and HLA-DRB1*1501 measurement in predicting the response to immunosuppressive therapy for aplastic anemia]. (18218241)
2007
37
Expression of interferon-gamma and tumor necrosis factor-alpha in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia. (15815907)
2005
38
Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. (15217832)
2004
39
Severe aplastic anemia with autoimmune thyroiditis showing no hematological response to intensive immunosuppressive therapy. (12624493)
2003
40
Sustained long-term complete remission in an elderly aplastic anemia patient after cessation of combined therapy consisting of granulocyte-colony stimulating factor and erythropoietin]. (10695398)
2000
41
N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/ paroxysmal nocturnal hemoglobinuria during evolution to clonal disease. (10627475)
2000
42
Aplastic anemia in pregnancy: treatment with cyclosporine and granulocyte-colony stimulating factor. (10326895)
1999
43
Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. (7532040)
1995
44
Ticlopidine and fatal aplastic anemia in an elderly woman. (7841572)
1994
45
In vitro effect of stem cell factor on colony growth from acquired severe aplastic anemia. (7691324)
1993
46
Granulocyte-macrophage colony-stimulating factor in the sera of patients with aplastic anemia. (8461622)
1993
47
Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF. (1373226)
1992
48
Correlation of response of aplastic anemia patients to antilymphocyte globulin with in vitro lymphocyte stimulatory effect: predictive value of in vitro test for clinical response. (2029581)
1991
49
Acquired myeloperoxidase deficiency of neutrophils in a patient with aplastic anemia (idiopathic marrow aplasia). (2844051)
1988
50
Idiopathic aplastic anemia in a dog. (15221686)
1985

Variations for Aplastic Anemia

About this section

Clinvar genetic disease variations for Aplastic Anemia:

5 (show all 31)
id Gene Variation Type Significance SNP ID Assembly Location
1TERTNM_198253.2(TERT): c.604G> A (p.Ala202Thr)SNVPathogenicrs121918661GRCh37Chr 5, 1294397: 1294397
2TERTNM_198253.2(TERT): c.2080G> A (p.Val694Met)SNVPathogenicrs121918662GRCh37Chr 5, 1279456: 1279456
3TERTNM_198253.2(TERT): c.2315A> G (p.Tyr772Cys)SNVPathogenicrs121918663GRCh37Chr 5, 1272367: 1272367
4TERTNM_198253.2(TERT): c.3268G> A (p.Val1090Met)SNVPathogenicrs121918664GRCh37Chr 5, 1254510: 1254510
5PRF1NM_001083116.1(PRF1): c.1163G> T (p.Ser388Ile)SNVPathogenicrs193302875GRCh37Chr 10, 72358314: 72358314
6SBDSNM_016038.2(SBDS): c.258+2T> CSNVPathogenic, risk factorrs113993993GRCh37Chr 7, 66459197: 66459197
7TERCTERC, 143G-ASNVPathogenicChr na, -1: -1
8TERCTERC, 212C-GSNVPathogenicChr na, -1: -1
9TINF2NM_001099274.1(TINF2): c.862T> C (p.Phe288Leu)SNVPathogenicrs199422317GRCh37Chr 14, 24709824: 24709824
10TERTNM_198253.2(TERT): c.2147C> T (p.Ala716Val)SNVPathogenicrs199422298GRCh37Chr 5, 1278895: 1278895
11TERTNM_198253.2(TERT): c.2537A> G (p.Tyr846Cys)SNVPathogenicrs199422302GRCh37Chr 5, 1268680: 1268680
12TERTNM_198253.2(TERT): c.2628C> G (p.His876Gln)SNVPathogenicrs199422303GRCh37Chr 5, 1266605: 1266605
13TERTNM_198253.2(TERT): c.2935C> T (p.Arg979Trp)SNVPathogenicrs199422305GRCh37Chr 5, 1260624: 1260624
14TERTNM_198253.2(TERT): c.3043T> C (p.Cys1015Arg)SNVPathogenicrs199422307GRCh37Chr 5, 1255516: 1255516
15TERTNM_198253.2(TERT): c.835G> A (p.Ala279Thr)SNVPathogenicrs61748181GRCh37Chr 5, 1294166: 1294166
16TERCNR_001566.1(TERC): n.117A> CSNVPathogenicrs199422273GRCh37Chr 3, 169482732: 169482732
17TERCNR_001566.1(TERC): n.178G> ASNVPathogenicrs199422275GRCh37Chr 3, 169482671: 169482671
18TERCNR_001566.1(TERC): n.180C> TSNVPathogenicrs199422276GRCh37Chr 3, 169482669: 169482669
19TERCNR_001566.1(TERC): n.28_34delGTGGTGGdeletionPathogenicrs199422259GRCh37Chr 3, 169482815: 169482821
20TERCNR_001566.1(TERC): n.305G> ASNVPathogenicrs199422279GRCh37Chr 3, 169482544: 169482544
21TERCNR_001566.1(TERC): n.322G> ASNVPathogenicrs199422280GRCh37Chr 3, 169482527: 169482527
22TERCNR_001566.1(TERC): n.323C> TSNVPathogenicrs199422281GRCh37Chr 3, 169482526: 169482526
23TERCNR_001566.1(TERC): n.391_392delCCdeletionPathogenicrs199422283GRCh37Chr 3, 169482457: 169482458
24TERCNR_001566.1(TERC): n.450G> ASNVPathogenicrs199422287GRCh37Chr 3, 169482399: 169482399
25TERCNR_001566.1(TERC): n.204C> GSNVPathogenicrs199422277GRCh37Chr 3, 169482645: 169482645
26TERCNR_001566.1(TERC): n.58G> ASNVPathogenicrs113487931GRCh37Chr 3, 169482791: 169482791
27TERCNR_001566.1(TERC): n.72C> GSNVPathogenicrs199422265GRCh37Chr 3, 169482777: 169482777
28TERCNR_001566.1(TERC): n.110_113delGACTdeletionPathogenicrs199422270GRCh37Chr 3, 169482736: 169482739
29TERCNR_001566.1(TERC): n.116C> TSNVPathogenicrs199422272GRCh37Chr 3, 169482733: 169482733
30TERCNR_001566.1(TERC): n.98G> ASNVPathogenicrs199422268GRCh37Chr 3, 169482751: 169482751
31TERCTERC, 325G-TSNVPathogenicChr na, -1: -1

Expression for genes affiliated with Aplastic Anemia

About this section
Search GEO for disease gene expression data for Aplastic Anemia.

Pathways for genes affiliated with Aplastic Anemia

About this section

GO Terms for genes affiliated with Aplastic Anemia

About this section

Cellular components related to Aplastic Anemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1small nucleolar ribonucleoprotein complexGO:000573211.0NHP2, NOP10
2nuclear telomere cap complexGO:000078311.0TERT, TINF2
3box H/ACA scaRNP complexGO:007258910.5DKC1, NHP2, NOP10
4box H/ACA telomerase RNP complexGO:009066110.5DKC1, NHP2, NOP10
5box H/ACA snoRNP complexGO:003142910.5DKC1, NHP2, NOP10
6telomerase holoenzyme complexGO:000569710.4DKC1, NHP2, NOP10, TERT
7nuclear chromosome, telomeric regionGO:000078410.4NBN, NHP2, TERT, TINF2
8extracellular spaceGO:000561510.0CD59, CSF2, EPO, IFNG, IL3, KITLG

Biological processes related to Aplastic Anemia according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of mast cell proliferationGO:007066811.0IL3, KITLG
2embryonic hemopoiesisGO:003516210.9IL3, KITLG
3positive regulation of hematopoietic stem cell proliferationGO:190203510.9KITLG, THPO
4positive regulation of myeloid leukocyte differentiationGO:000276310.9IL3, KITLG
5thrombopoietin-mediated signaling pathwayGO:003816310.8MPL, THPO
6positive regulation of interleukin-23 productionGO:003274710.8CSF2, IFNG
7positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.7CSF2, EPO, IL3
8positive regulation of telomere maintenanceGO:003220610.7NBN, TINF2
9snRNA pseudouridine synthesisGO:003112010.6DKC1, NHP2
10positive regulation of telomerase RNA localization to Cajal bodyGO:190487410.6DKC1, NHP2, NOP10
11rRNA pseudouridine synthesisGO:003111810.5DKC1, NHP2, NOP10
12positive regulation of Ras protein signal transductionGO:004657910.5EPO, KITLG
13telomere maintenance via telomeraseGO:000700410.4DKC1, NHP2, NOP10, TERT
14positive regulation of DNA replicationGO:004574010.4CSF2, EPO, IL3, KITLG
15positive regulation of cell proliferationGO:000828410.1CSF2, EPO, IFNG, IL3, KITLG
16cell proliferationGO:00082839.8DKC1, KITLG, MPL, NBN, SBDS, THPO

Molecular functions related to Aplastic Anemia according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1telomerase activityGO:000372010.9DKC1, TERT
2box H/ACA snoRNA bindingGO:003451310.8DKC1, NHP2, NOP10
3Ras guanyl-nucleotide exchange factor activityGO:000508810.8CSF2, IL3, KITLG
4telomerase RNA bindingGO:007003410.8DKC1, NHP2, NOP10, TERT
5growth factor activityGO:000808310.7CSF2, IL3, KITLG, THPO
6cytokine activityGO:000512510.7CSF2, IFNG, IL3, KITLG, THPO
7protein bindingGO:00055159.3CD55, CD59, CSF2, DKC1, EPO, IFNG

Sources for Aplastic Anemia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet